Eastman Kodak ein Vervielfachungskandidat ?

Eastman Kodak (NYSE:KODK) soars 324% in morning trading after the Wall Street Journal reports the company won a $765M government loan under the Defense Production Act to help speed the domestic production of drugs that can treat a range of medical conditions and reduce U.S. reliance on foreign sources.
Kodak, once a giant in photography, is readying production of ingredients for generic drugs, including the antimalarial drug hydroxychloroquine that President Trump has plugged as a treatment for COVID-19.
The loan, which comes from the U.S. International Development Finance Corp. —
a government agency similar to a bank —  is the first of its kind under the DPA.
The loan, similar to a commercial loan, must be repaid over 25 years, Kodak CEO Jim Continenza told the WSJ.
The company will make "starter materials" and "active pharmaceutical ingredients" used to make generic drugs.
For the bull case on the stock, see Eastman Kodak Company: A Potential Turnaround Around The Corner.


 

POTUS fährt dem Deep State aber so richtig in die Parade ..... Bill Gates ;Fauci; WHO sowie die Democ(rats) drehen so richtig am Rad .....Sie werden mit ihrem gechippten Impfstoff keinen Cent verdienen.  Schade nur dass ich nicht online war um die Pressekonferenz von Trump Gestern zu verfolgen um hier frühzeitig investiert zu sein.      

Werden sich gut entwickeln-Vervielfacher möglich.
Ein" Geschmaeckle" hat die Story.SEC wird sich mit Trump allerdings nicht anlegen!!!!!  

CEO von "Eastman Kodak" James Continenza im Interview vom 29. Juli 2020

https://aktien-boersen.blogspot.com/2020/07/...-james-continenza.html  

wer hätte das gedacht. Krass. Hoffe der ein oder andere ist unter $10 rein gekommen.
$51..
Zu früh verkauft. Hab mich nicht befasst was hier passiert. Aber es wurde auch extrem geshortet und die covern momentan. Die hats ordentlich erwischt...  

Chance heute morgen verpasst. Aber das ist mal nen Brett! Jetzt erst mal halted.  

 

3.Buy: $9,88
3.Sell: $56,88
+444%
Vol.: 200K
The moment of surprise was at the couriers - pressed without limit.

S F

 

Das ist doch nur nach albern. Der Anstieg ist in dem Maße nicht einmal im Ansatz gerechtfertigt.  

zur Zeit dürfe nur sehr wenig auch nur im Ansatz gerechtfertig sein. Alles eine Frage der Phantasie  

Continenza soll man mal schön für Insiderhandel drankriegen. Ist sicher nur ein Zufall, dass der sich letzte Woche fett eingedeckt hat. Gibt auch noch einige andere, die sich in den letzten 2-3 Tagen eingekauft haben. Die wussten natürlich auch alle nichts von der Nachricht. Der Rest ist dann Robinhood Verselbstständigung.  

 

Richtige Verarsche. Hier wussten einige zu 100% vorher bescheid...

Wie kommt man an solchen informationen....

Das durchschnittliche Wolumen war ein tag davor bei 1,7mil normal sind 80.000  

...unverhofft US Kohle kriegen?  

wenn die alten Aktien noch handelbar wären. Ich hätte theroretisch noch 3000 Stück. :-(

 

Von den Amis wie immer abgezockt. Warum jagt man den Kurs hoch bevor die Amis loslegen? Gestern ca. mit 33 dolar geschlossen macht ca. 27 Euro.  

hat jetzt einen wert von ca. 1,7 milliarden euro, ok bei 765 millionen stütze, die auch zurück bezahlt werden müssen, nicht alles, aber grösster teil, da müssen kodak schon richtig produzieren, und zum teil auch noch für trumps lieblingsmittel, was als nicht effektiv galt, und hinzu kommt noch die produktionseinrichtungszeit von bis 4 jahren,sage nur falls die fertig werden ist der betrag aufgebraucht und schulden zu, also nächste insolvent, wie kurz davor 2012,vorprogramiert, auch kommt die unsicherheit dazu wer das rennen in der welt mit dem impsstoff gewinnt, will nicht über die aktie herziehen, allen glückwunsch, die jetzt abfischen konnten, interressiert zwar nicht, aber ich hatte dienstag abend bei nash für 8,70 doll gekauft und gestern für 42,80 doll verkauft,  

TECHNOLOGY

Commodities

News Wire

Company News
19m ago

Kodak Pivots to Drugs After Failing at Photography and Crypto
Eric Newcomer and Michael Tobin, Bloomberg News




(Bloomberg) -- Eastman Kodak Co. is getting another shot at redemption.

The 131-year-old company that once dominated the market for photographic film and made an ill-fated foray into cryptocurrencies is pivoting again. This time, Kodak plans to make ingredients for generic drugs, aided by a $765 million U.S. government loan, the first fruits of a Trump Administration program aimed at bolstering American drug-making capabilities in the age of Covid-19.

News of the arrangement fueled a rally of as much as 2,760% for Kodak stock this week, with legions of day traders snapping up shares through the Robinhood Markets Inc.’s trading app.

But some financial analysts and economic development experts greeted the proposal with skepticism. Kodak filed for bankruptcy in 2012 after getting lapped by rivals in digital photography and failing to make good on an earlier multibillion-dollar acquisition of a pharmaceutical company. It also has little to show for the planned introduction of a cryptocurrency two years ago. Why, then, would the government pick Kodak to spearhead efforts to reinvigorate a pharmaceutical production supply chain in the United States?

“We are puzzled by the Trump Administration’s decision,” analysts at SVB Leerink wrote in a research note. “In particular, we find it puzzling why generic pharmaceutical companies who have the capabilities and know-how for this have not yet been awarded such contracts.”

Production of active pharmaceutical ingredients for generics is a “herculean task,” they wrote. Ami Fadia, a senior analyst at SVB Leerink, said Kodak is “not even on the list” of companies she would have envisioned for such a loan.

Trump administration officials and New York Governor Andrew Cuomo lauded the planned loan, administered by the U.S. International Development Finance Corporation under the auspices of the Defense Production Act. “It’s going to be the renaissance of the great state of New York as an industrial power,” Peter Navarro, President Trump’s trade adviser, said in a Tuesday interview with Fox Business. “And it’s going to give the people of our country some assurance that when push comes to shove in pandemics like this we won’t see what we’re seeing right now is over 75 countries restricting the sale of pharmaceuticals, or something, to us like face masks.”

Cuomo said the arrangement would result in the creation of 300 jobs. “Kodak has a long storied history in New York State, and we’ve been working with them to develop an even brighter future,” he said in a video presentation.

Plans for the loan got underway soon after May 14, when Trump signed an executive order calling for the expansion of “the domestic production of strategic resources needed to respond to the Covid-19 outbreak, or to strengthen any relevant domestic supply chains.”

Navarro said in the Fox Business interview that one of his staff, Christopher Abbott, a recent graduate of American University, identified Kodak as a prospect. Navarro’s office then brought Kodak to the attention of Adam Boehler, a former health care entrepreneur who heads the International Development Finance Corporation, Boehler said in an interview.

From there, DFC reviewed Kodak’s application, with Trump and Navarro keenly tracking progress, according to David Glaccum, who oversees the domestic investment effort. Navarro’s office didn’t return a request for comment.

The camera company officially filed an application for the new program in mid-June, Glaccum said. The group began to review the application with assistance from the Department of Health and Human Services and the Department of Defense. “They provide us with questions on the technical sides,” Glaccum said. “We’re finance folks, so we really rely on our interagency colleagues.”

The DFC saw two strengths to the deal: One, it believes that Kodak already has the equipment to produce the drug materials. Currently, 1%-3% of Kodak’s revenue comes from manufacturing materials for drugs. “The second thing is they had an advanced purchase order lined up,” Boehler said. He and Glaccum declined to identify the company that agreed to purchase drug materials. Kodak said it has a letter of intent for the deal.

While the DFC and Kodak have signed a letter of interest, the group hasn’t finalized the loan terms and said it won’t disclose them. “I think it’s priced like a commercial loan would be to the extent they could get one,” Glaccum said.

Kodak’s Executive Chairman James Continenza said in an interview with CNBC he’s confident the loan will go through. “One of our core competencies has always been chemistry, for over 100 years we’ve been doing chemistry,” Continenza said. “We realized we could do more. The government realized they could do more. They kind of reached out, and we found a path that makes a lot of sense for the American public to help bring the pharmaceutical protections back to America.”

Continenza and board member Philippe Katz bought Kodak shares in June. Continenza bought almost 47,000 shares, while Katz bought 10,000 shares in two separate transactions. David Bullwinkle, the company’s CFO, purchased almost 2,900 shares in May. Kodak said Continenza’s purchases are a continuation of “ongoing, regular investments in Kodak and are in full compliance with regulatory guidelines for investment activity.”

News of the planned loan leaked Monday though at least one local publication, RochesterFirst.com, which later deleted the story and an associated tweet. The same day, 1.65 million Kodak shares changed hands, compared with just under 75,000 shares on Friday.

This wouldn’t be Kodak’s first attempt at pharmaceuticals. Kodak entered the business in 1988 with the acquisition of Sterling Drug Inc. for $5.1 billion. The deal had a similar rationale: Kodak would apply its expertise in chemicals to pharmaceuticals. “For Kodak shareowners, the merger will accelerate our entry into the $110 billion-plus worldwide pharmaceutical industry,” Colby Chandler, Kodak chairman and chief executive said at the time. “And it will provide us with attractive long-term sales and earnings potential.”

Six years later, Kodak sold the business unit in two pieces for about $500 million less than it paid.

Kodak filed for bankruptcy almost a decade ago after moving too slowly to embrace digital photography; it also worked on a small nuclear reactor for decades in a basement on its corporate campus. In 2018, during a period of cryptocurrency mania, Kodak announced that, with a partner, it would release a digital currency, the KodakCoin. The announcement sent the stock price soaring. Quickly one-third of Kodak’s shares were held by short-sellers, Bloomberg reported at the time. The cryptocurrency was later declared a failure.

Adding to concerns about Kodak’s prospects are questions around the talent pool in and near Rochester, said Prashant Yadav, an expert in medical and pharmaceutical supply chains and a senior fellow at the Center for Global Development. Other successful medical ingredients companies have been built in places where there’s greater expertise, he said.

He also wondered why the U.S. government is prioritizing making drug ingredients rather than investing in Covid-19 testing production. Yadav asked, “What else could have happened” with the money?  

kodak an erster stelle,nehme mal an mit beginn usa treiben die den kurs um dann vorlåufig das letzte mal abzufassen, werden volatile zeiten heute abend, um sich dann mit den gegenwärtigen preis zu beruhigen  

viel yzu viel gepushe von den medien seit dienstag, frage mich bloss weshalb die aktie am dienstag nicht höher ging, vielleicht weil sich noch nicht soviele medien drauf gestürzt hatten, der deal wurde da ja schon erwähnt, schade, dass es soweit kam, wäre für viele altanleger eine alternative, aber momentan denke ich nur gepusche,  

Gleich geht das Massaker los. Ich habe nicht investiert und schaue mir das gleich gemütlich an.  

 

 

 

hieße er Eastman Kodak...
Da laufen mehrere Ordermaschinen parallel.
TOTAL überbewertet. Genauso wie OCUGEN.

S F